Dr. Dholaria on the Rationale for the MagnetisMM-1 Trial in Multiple Myeloma

Video

In Partnership With:

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Bhagirathbhai Dholaria, MBBS, assistant professor of medicine, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses the rationale for the phase 1 MagnetisMM-1 trial (NCT03269136) in relapsed/refractory multiple myeloma.

Novel therapies are needed to improve outcomes for patients with relapsed/refractory multiple myeloma, Dholaria explains. The MagnetisMM-1 study evaluated the safety and efficacy of the novel bispecific antibody elranatamab (PF-06863135) alone and in combination with immunomodulatory agents, such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), in patients with relapsed/refractory multiple myeloma.

Currently, the data are not mature enough to draw conclusions as to whether elranatamab stands out among other BCMA-directed bispecific antibodies being evaluated in similar ongoing clinical trials, Dholaria explains. Many of these agents have demonstrated efficacy, as well as tolerability, among patients with relapsed/refractory multiple myeloma.

Elranatamab is being evaluated as a single agent in the ongoing phase 2 MagnetisMM-3 trial (NCT04649359).

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS